NCT04008082View on ClinicalTrials.gov

A Study of Overall Survival in Participants With Unresectable Hepatocellular Carcinoma

CompletedOBSERVATIONAL
Enrollment

412

Participants

Timeline

Start Date

May 14, 2019

Primary Completion Date

January 28, 2022

Study Completion Date

January 28, 2022

Conditions
Carcinoma, HepatocellularCarcinomaNeoplasms, Glandular and EpithelialNeoplasms
Interventions
DRUG

Lenvatinib

Lenvatinib capsule.

Trial Locations (2)

Unknown

Eisai Trial Site #1, Osaka

Eisai Trial Site #2, Tokyo

All Listed Sponsors
lead

Eisai Co., Ltd.

INDUSTRY

NCT04008082 - A Study of Overall Survival in Participants With Unresectable Hepatocellular Carcinoma | Biotech Hunter | Biotech Hunter